A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body\'s own immune system to control cancer) as a possible treatment for hormone receptor positive breast cancer. The interventions involved in this study are: * Pembrolizumab (MK-3475; Keytruda™) * Nab-Paclitaxel (Abraxane
Epistemonikos ID: 6ef0cdffb1085431d1250b87e0c0fb4fe1eddff8
First added on: May 20, 2024